GLP-1 RAs: Unlocking Pleiotropic Potential – Advancing Clinical Applications Beyond Glycemic Management​

The role of GLP-1 (glucagon-like peptide-1) extends far beyond its metabolic origins, with groundbreaking research uncovering a spectrum of pleiotropic effects that are redefining its therapeutic potential. This educational session will highlight cutting-edge studies on GLP-1 receptor agonists (GLP-1 RA) impact on cardiovascular function, neuroinflammation, and cognitive health, alongside its emerging applications in behavioral health domains such as mood regulation, substance use disorders, and appetite control. Participants will gain a comprehensive understanding of the pathways driving these diverse effects and explore the translational implications for clinical practice. Practical considerations for integrating GLP-1 RA therapies into multidisciplinary care models will also be discussed, empowering healthcare providers to optimize patient outcomes in innovative and holistic ways. 

Moderator: Vi T. Gilmore, Pharm.D. Internal Medicine Clinical Pharmacy Specialist, Johns Hopkins Hospital; Baltimore, Maryland   View Biography

Examining the Evidence: GLP-1 RA Therapies for Cardiovascular, Kidney, and Liver Health 2:15 p.m. to 3:00 p.m. Speaker: Allison Presnell, Pharm.D., BCACP, BC-ADM

Examining the Evidence: GLP-1 RA Therapies in Behavioral Health and Neurocognitive Disorders 3:00 p.m. to 3:45 p.m. Speaker: Heather P. Whitley, Pharm.D., FCCP, BCPS, CDCES Clinical Professor Auburn University Harrison College of Pharmacy Auburn, Alabama   View Biography